BlueRed Partners is an MAS registered fund management company, seeking to connect deep-technology Israeli startups to our high-profile LPs.
At BlueRed Partners, we believe that every investment is an active one. With LPs that are key players in their respective industries, we seek to develop and grow novel Israeli technologies into the Asian sphere, allowing our regional communities to benefit early on from technological disruption.
With a wealth of experience in the financial and technology sectors, our team has a successful track record of investment in Israel and abroad, and ensures efficient and successful navigation through a notoriously challenging investment landscape in order to maximize returns for our investors.
At BlueRed Partners, we believe that every investment is an active one. With LPs that are key players in their respective industries, we seek to develop and grow novel Israeli technologies into the Asian sphere, allowing our regional communities to benefit early on from technological disruption.
With a wealth of experience in the financial and technology sectors, our team has a successful track record of investment in Israel and abroad, and ensures efficient and successful navigation through a notoriously challenging investment landscape in order to maximize returns for our investors.
Location: Singapore
Employees: 1-10
Founded date: 2017
Portfolio 2
| Date | Name | Website | Total Raised | Location |
| 24.05.2023 | Incredo Su... | incredosugar.com | $30M | United Sta... |
| 24.05.2023 | DouxMatok | douxmatok.com | $60.1M | Israel |
Mentions in press and media 3
| Date | Title | Description |
| 24.05.2023 | BREAKING: Incredo (formerly DouxMatok) raises $30m series C: ‘We’re the cheapest sugar reduction solution on the market’ | DouxMatok, the Israeli firm behind patented technology that makes sugar taste sweeter, has rebranded as Incredo and raised $30 million in a series C round to expand its sugar reduction platform. The funding round was led by dsm firmenich Ve... |
| 22.11.2021 | RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line | JERUSALEM, Nov. 22, 2021 /PRNewswire/ -- RenalSense™, a leader in real-time renal diagnostics, today announced it has secured $14M to bolster the global commercialization of its current product, the Clarity RMS, expand clinical validation t... |
| 22.11.2021 | RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line | JERUSALEM, Nov. 22, 2021 /PRNewswire/ -- RenalSense™, a leader in real-time renal diagnostics, today announced it has secured $14M to bolster the global commercialization of its current product, the Clarity RMS, expand clinical validation t... |